当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Logan Kshatriya
Renal Cell Carcinoma is a common form of kidney cancer that traditionally required radical nephrectomy, the complete removal of the affected kidney. However, recent advancements in medical science and surgical techniques have paved the way for renal preservation therapy, also known as nephron-sparing surgery or partial nephrectomy. This revolutionary approach aims to preserve kidney function while effectively treating the cancer. This article provides an overview of renal preservation therapy, highlighting its advantages such as kidney function preservation, minimized surgical complications, enhanced oncological outcomes, and expanded future treatment options. The various surgical techniques and advancements in imaging technology are discussed, along with considerations for patient selection. Renal preservation therapy represents a significant breakthrough in RCC treatment, offering improved quality of life and reduced long-term complications for patients.